Ibaraki, Japan

Kyosuke Kitoh


Average Co-Inventor Count = 8.3

ph-index = 7

Forward Citations = 138(Granted Patents)


Location History:

  • Kawague, JP (1981)
  • Kawagoe, JP (1981 - 1983)
  • Saitama, JP (1984)
  • Ibaraki, JP (1985 - 1998)

Company Filing History:


Years Active: 1981-1998

Loading Chart...
25 patents (USPTO):Explore Patents

Title: Innovations of Kyosuke Kitoh in Antitumor Derivatives

Introduction

Kyosuke Kitoh, an esteemed inventor based in Ibaraki, Japan, is recognized for his significant contributions to the field of pharmaceutical compounds, particularly in the development of novel antitumor agents. With a portfolio of 25 patents, Kitoh's innovative work has held a promising potential in combating cancer through unique chemical structures.

Latest Patents

Among Kyosuke Kitoh's latest contributions is his development of tricyclic heterocyclic sulfonamide and sulfonic ester derivatives. These compounds have been shown to possess excellent antitumor activity and are represented by a specific general formula detailing their chemical composition. The novelty of these tricyclic heterocyclic sulfonamide derivatives lies in their intricate structures, which include aromatic rings and unsaturated cycles, significantly enhancing their therapeutic properties.

Career Highlights

Kitoh's career is marked by his affiliation with Eisai Company, Limited, a leading pharmaceutical firm where he applies his expertise in medicinal chemistry. His work has not only resulted in multiple patents but has also paved the way for advancements in drug development strategies, making impactful strides in oncology.

Collaborations

Throughout his career, Kyosuke Kitoh has collaborated with talented colleagues, including Yoshimasa Machida and Shigeto Negi. These partnerships have amplified his research capabilities, leading to the synthesis of various innovative compounds aimed at improving health outcomes for cancer patients.

Conclusion

Kyosuke Kitoh's inventive prowess in the realm of antitumor derivatives signifies the vital intersection of science, collaboration, and innovation. His remarkable patents and ongoing research continue to push the boundaries of pharmaceutical developments, contributing to the global fight against cancer and enhancing therapeutic options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…